Adalimumab efficacy in enteropathic spondyloarthritis: A 12-mo observational multidisciplinary study

Table 4 Correlations between the scores of clinimetric tests for articular-gastrointestinal activity and patient reported outcomes of health-related quality of life scores

	CDAI	pMAYO	IBDQ	BASDAI	BASFI	ASDAS-CRP	PtGA	HAQ	Sf-36/ PCS	Sf-36/ MCS	CRP
At baseline
CDAI	1	1	-0.57b	0.19	0.29	0.21	0.14	0.12	-0.24	-0.33	0.35
pMAYO	1	1	-0.48a	0.34	0.38	0.37	0.15	0.18	-0.14	-0.11	0.28
IBDQ	-0.57b	-0.48a	1	-0.38b	-0.34a	-0.52b	-0.26	-0.19	0.27	0.67b	-0.26
BASDAI	0.19	0.34	-0.38b	1	0.64b	0.69b	0.24	0.26	-0.22	-0.31a	0.00
BASFI	0.29	0.38	-0.34a	0.64b	1	0.57b	0.37b	0.36b	-0.44b	-0.15	0.37b
ASDAS-CRP	0.21	0.37	-0.52b	0.69b	0.57b	1	0.37b	0.36b	-0.30a	-0.41b	0.32a
PtGA	0.14	0.15	-0.26	0.24	0.37b	0.37b	1	0.22	-0.14	-0.22	0.14
HAQ	0.12	0.18	-0.19	0.26	0.36b	0.36b	0.22	1	-0.46b	-0.03	0.07
Sf-36/PCS	-0.24	-0.14	0.27	-0.22	-0.44e	-0.30a	-0.14	-0.46b	1	0.05	-0.13
Sf-36/MCS	-0.33	-0.11	0.67b	-0.31a	-0.15	-0.41b	-0.22	-0.03	0.05	1	-0.08
After 12 mo of therapy with adalimumab (ES-AN/Ada cohort)
CDAI	1	1	-0.83b	0.16	0.56a	0.54a	0.53a	0.53a	-0.71b	-0.67b	0.75b
pMAYO	1	1	-0.51	0.18	0.49	0.17	0.56	-0.29	-0.14	-0.25	0.6
IBDQ	-0.83b	-0.51	1	-0.23	-0.56b	-0.55b	-0.61b	-0.36a	0.53b	0.66b	-0.52b
BASDAI	0.16	0.18	-0.23	1	0.58b	0.68b	0.51b	0.39a	-0.52b	-0.11	-0.14
BASFI	0.56a	0.49	-0.56b	0.58b	1	0.56b	0.64b	0.54b	-0.52b	-0.45a	0.16
ASDAS-CRP	0.54a	0.17	-0.55b	0.68b	0.56b	1	0.67b	0.38a	-0.62b	-0.41a	0.31
PtGA	0.53a	0.56	-0.61b	0.51b	0.64b	0.67b	1	0.51b	-0.37a	-0.59b	0.26
HAQ	0.53a	-0.29	-0.36a	0.39a	0.54b	0.38a	0.51b	1	-0.47b	-0.40a	0.10
Sf-36/PCS	1	1	-0.83b	0.16	0.56a	0.54a	0.53a	0.53a	-0.71b	-0.67b	0.75b
Sf-36/MCS	1	1	-0.51	0.18	0.49	0.17	0.56	-0.29	-0.14	-0.25	0.60
CRP	-0.83b	-0.51	1	-0.23	-0.56b	-0.55b	-0.61b	-0.36a	0.53b	0.66b	-0.52b

Correlations between variables were assessed in the 30 patients with enteropathic spondyloarthritis from Ancona, Italy, at baseline and after 6 mo (data not shown) and 12 mo of therapy with adalimumab (ES-AN/Ada), using Pearson’s correlation coefficient;

^aP < 0.05,

^bP < 0.01. ASDAS-CRP: Ankylosing Spondylitis Disease Activity Score-C-Reactive Protein; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; CDAI: Crohn’s Disease Activity Index; CRP: C-Reactive Protein; HAQ: Health Assessment Questionnaire; IBDQ: Inflammatory Bowel Disease Questionnaire; pMAYO: partial Mayo score; PtGA: Patient Global Assessment; SF-36/MCS: Summary of “Mental Component Score” of the Short Form-36 health survey; SF-36/PCS: Summary of “Physical Component Score” of the Short Form-36 health survey.